Xizang Haisco Pharmaceutical Group Co Ltd (SHE:002653) — Market Cap & Net Worth
Market Cap & Net Worth: Xizang Haisco Pharmaceutical Group Co Ltd (002653)
Xizang Haisco Pharmaceutical Group Co Ltd (SHE:002653) has a market capitalization of $9.59 Billion (CN¥65.55 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #2305 globally and #278 in its home market, demonstrating a 0.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xizang Haisco Pharmaceutical Group Co Ltd's stock price CN¥58.53 by its total outstanding shares 1119917970 (1.12 Billion). Analyse Xizang Haisco Pharmaceutical Group Co Lt cash flow conversion to see how efficiently the company converts income to cash.
Xizang Haisco Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Xizang Haisco Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $3.15 Billion to $9.59 Billion (10.78% CAGR).
Xizang Haisco Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xizang Haisco Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.46x
Xizang Haisco Pharmaceutical Group Co Ltd's market cap is 1.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.78x
Xizang Haisco Pharmaceutical Group Co Ltd's market cap is 13.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.15 Billion | $1.21 Billion | $372.16 Million | 2.60x | 8.46x |
| 2016 | $2.28 Billion | $1.44 Billion | $442.78 Million | 1.59x | 5.16x |
| 2017 | $1.72 Billion | $1.86 Billion | $237.55 Million | 0.93x | 7.25x |
| 2018 | $1.84 Billion | $3.43 Billion | $333.23 Million | 0.54x | 5.53x |
| 2019 | $3.21 Billion | $3.94 Billion | $493.89 Million | 0.81x | 6.49x |
| 2020 | $2.77 Billion | $3.33 Billion | $636.62 Million | 0.83x | 4.35x |
| 2021 | $3.27 Billion | $2.77 Billion | $345.06 Million | 1.18x | 9.47x |
| 2022 | $3.61 Billion | $3.02 Billion | $277.07 Million | 1.20x | 13.02x |
| 2023 | $3.75 Billion | $3.36 Billion | $295.11 Million | 1.12x | 12.72x |
| 2024 | $5.45 Billion | $3.72 Billion | $395.46 Million | 1.46x | 13.78x |
Competitor Companies of 002653 by Market Capitalization
Companies near Xizang Haisco Pharmaceutical Group Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Xizang Haisco Pharmaceutical Group Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Xizang Haisco Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Xizang Haisco Pharmaceutical Group Co Ltd's market cap moved from $3.15 Billion to $ 9.59 Billion, with a yearly change of 10.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥9.59 Billion | +14.05% |
| 2025 | CN¥8.41 Billion | +54.35% |
| 2024 | CN¥5.45 Billion | +45.20% |
| 2023 | CN¥3.75 Billion | +4.05% |
| 2022 | CN¥3.61 Billion | +10.34% |
| 2021 | CN¥3.27 Billion | +18.08% |
| 2020 | CN¥2.77 Billion | -13.64% |
| 2019 | CN¥3.21 Billion | +73.95% |
| 2018 | CN¥1.84 Billion | +7.07% |
| 2017 | CN¥1.72 Billion | -24.65% |
| 2016 | CN¥2.28 Billion | -27.47% |
| 2015 | CN¥3.15 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Xizang Haisco Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.59 Billion USD |
| MoneyControl | $9.59 Billion USD |
| MarketWatch | $9.59 Billion USD |
| marketcap.company | $9.59 Billion USD |
| Reuters | $9.59 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. The company offers pharmaceutical products in the areas of anesthesia and analgesia, diabetes mellitus and complications, tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and respiratory, narcotic analgesics, endocrine system, enteral parenteral,… Read more